Category: BLUE:NASDAQ

After Bristol-Myers Squibb Buys Celgene What’s Next? JP Morgan’s Conference Will Answer That

The Bristol-Myers Squibb/Celgene merger has started 2019 with a bang in both healthcare and on Wall Street. A good hint as to what happens next starts during JP Morgan’s 37th Annual Healthcare Conference and the debate over the winners and losers for p…